DCGI Suspends Entod Pharmaceuticals' Eye Drop Manufacturing Permission

The Drug Controller General of India (DCGI) has suspended Entod Pharmaceuticals' authorization to manufacture and market its new eye drops intended to reduce dependency on reading glasses. The suspension follows claims made by the company that were not approved by the Central Licensing Authority. Entod's CEO, Nikkhil K Masurkar, announced plans to challenge the suspension in court.

The Drug Controller General of India (DCGI) has taken significant action by suspending Entod Pharmaceuticals' permission to manufacture and sell eye drops aimed at reducing the need for reading glasses in adults suffering from presbyopia. This measure stems from the company's unapproved claims regarding their product, Pilocarpine Hydrochloride Ophthalmic Solution USP 1.25% w/v.

According to the DCGI, Entod Pharmaceuticals did not obtain the necessary approval from the Central Licensing Authority to substantiate their product claims. Entod's CEO, Nikkhil K Masurkar, vehemently denied any wrongdoing and declared the company's intention to challenge the suspension in court, asserting that no unethical or false information was presented to the public.

The controversy centers around various assertions made by Entod Pharmaceuticals regarding their eye drops, which they advertised as a non-invasive option to improve near vision and reduce dependency on reading glasses. The DCGI pointed out that these claims were made without proper authorization, leading to potential public misinformation.

(With inputs from agencies.)